JAK1 and neoplasm: Afatinib inhibited LYVE-1, VEGFR2, VEGFR3, VEGFC, VEGF, VEGFA and CCR7 expression and the JAK1,2/STAT3 and FAK signalling pathways in HCC827 xenograft tumour tissues